ANI PHARMACEUTICALS INC (ANIP): Results of Operations and Financial Condition
ANI PHARMACEUTICALS INC (ANIP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results • Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-year • Purified Cortrophin ® Gel net revenues of $117.1 million, an increase of 43.5% year-over-year • Quarterly GAAP n
How this was made
The 30-second read
Why it matters
Traders can use the disclosed Q2 performance and the updated Cortrophin Gel net revenue guidance range to reassess near-term expectations for revenue mix, margin trajectory, and the credibility of the gout expansion sales force rollout.
Market read
Record Q2 results and reaffirmed full-year guidance, alongside a specific Cortrophin Gel guidance update, provide actionable inputs for valuation and trade sizing in ANIP.
What to watch
Gross margin declined on both GAAP and non-GAAP bases, and ILUVIEN revenue fell due to international shipment timing, which could offset gains if shipment normalization lags.
ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
Total net revenues increased 25.9% year-over-year to $266.0 million, Cortrophin Gel net revenues increased 43.5% to $117.1 million, GAAP net income attributable to common shareholders rose to $24.7 million from $8.1 million, and adjusted non-GAAP EBITDA increased 32.4% to $71.6 million. The company reaffirmed total net revenue and adjusted non-GAAP EBITDA guidance while reducing Cortrophin Gel net revenue guidance.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total net revenuesother | $266.0 million | – | 25.9% |
| Rare Disease total net revenuesother | $135,844 (in thousands) | – | 30.7% |
| Rare Disease and Brands total net revenuesother | $165,388 (in thousands) | – | 41.2% |
| Generics and Other total net revenuesother | $100,656 (in thousands) | – | 6.8% |
| GAAP gross marginGAAP | 62.4% | – | – |
| Non-GAAP gross marginnon-GAAP | 62.6% | – | – |
| GAAP research and development expensesGAAP | $14.7 million | – | decreased 10.8% |
| Non-GAAP research and development expensesnon-GAAP | $14.1 million | – | decreased 11.4% |
| GAAP selling, general, and administrative expensesGAAP | $91.7 million | – | increased 12.1% |
| Non-GAAP selling, general, and administrative expensesnon-GAAP | $80.7 million | – | increased 20.2% |
| Net income attributable to common shareholdersGAAP | $24.7 million | – | – |
| Diluted income per shareGAAP | $1.05 per diluted share | – | – |
| Adjusted diluted earnings per sharenon-GAAP | $2.21 | – | – |
| Adjusted EBITDAnon-GAAP | $71.6 million | – | 32.4% |
| Cash flow from operationsGAAP | $115.0 million | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Cortrophin GelYear-over-year growth was driven primarily by the existing specialty areas of Nephrology, Neurology, Ophthalmology, Pulmonology and Rheumatology. Growth was also attributed to increased volume. | $117.1 million | – | 43.5% |
| ILUVIEN and YUTIQThe decrease was based primarily on timing of international shipments. There were no sales of YUTIQ during the quarter ended June 30, 2026, as the Company transitioned promotional efforts in the U.S. from YUTIQ to ILUVIEN. | $18,718 (in thousands) | – | (16.1)% |
| BrandsReflecting a normalization in demand for certain products. | $11.8 million | – | (10.5)% |
| Brand royalties and other revenuesComprised of $9.7 million of royalties on net sales of pitolisant-based products and $8.0 million based upon work completed toward certain development milestones under the Harmony Agreement. | $17.7 million | – | 100.0% |
| Generic pharmaceutical productsDriven by continued strength in the partnered generic launch that commenced in the third quarter of 2025, contribution from new product launches, and commercial and operational outperformance. | $99.1 million | – | 9.7% |
| Other generic revenuesDriver not specified. | $1,605 (in thousands) | – | (59.0)% |
Full Year 2026 outlook
- RevenueTotal Company net revenue of $1,080 million - $1,140 million
- Gross margintotal company adjusted non-GAAP gross margin between 59.9% and 60.9%
- Tax rateannual U.S. GAAP effective tax rate of between 26% and 28%
- NoteCortrophin Gel net revenue of $520 million - $540 million
- NoteILUVIEN net revenue of $78 million - $83 million
- NoteAdjusted non-GAAP EBITDA of $285 million - $300 million
- NoteAdjusted non-GAAP diluted EPS of $9.19 - $9.69
- Noteapproximately 21.5 million and 21.8 million shares outstanding for the purpose of calculating full year adjusted non-GAAP diluted EPS
- Notetax effect non-GAAP adjustments for computation of adjusted non-GAAP diluted earnings per share utilizing a tax rate of 26%
Capital returns
- Effective on May 8, 2026, ANI’s board of directors authorized a share repurchase program to repurchase up to $100.0 million in common stock through May 2029.
What drove it
- Cortrophin Gel growth was driven primarily by the existing specialty areas of Nephrology, Neurology, Ophthalmology, Pulmonology and Rheumatology.
- The Cortrophin Gel gout sales-force expansion targeting podiatrists and primary care physicians was fully operational as of the end of June.
- Over 95% of reps generated multiple new patient cases, and over a third of prescribers initiated two or more cases in the gout expansion.
- Generics growth reflected new product launches, including a partnered generic launch that commenced in the third quarter of 2025.
- The Company launched 12 new Generics products year-to-date and is on track for at least 15 new product launches in 2026.
- Harmony Agreement revenue included development-milestone work and royalties on net sales of pitolisant-based products.
Concerns
- GAAP gross margin decreased from 64.7% to 62.4%, and non-GAAP gross margin decreased from 64.9% to 62.6%.
- Margin declines were primarily due to higher sales of royalty bearing products, including Cortrophin Gel and a partnered generic product, and the non-recurrence of prior-year revenues from Prucalopride.
- ILUVIEN net revenues decreased 16.1% primarily because of timing of international shipments.
- Brands net revenues decreased 10.5%, reflecting normalization in demand for certain products.
- Cortrophin Gel net revenue guidance was revised to $520 million - $540 million from $540 million - $575 million.
What to watch
- Momentum in Cortrophin Gel’s existing specialties, where the Company reported a record number of new cases initiated in July.
- Conversion and breadth of prescribing from the acute gouty arthritis expansion among podiatrists and primary care physicians.
- Completion of the balance of Harmony Agreement development work in the third quarter of 2026 and recognition of an additional $2.0 million in development milestone revenue.
- Detailed results and additional analyses from the SYNCHRONICITY clinical trial, anticipated at a retina-specialist medical conference in the fourth quarter of 2026.
- Delivery of at least 15 new Generics product launches in 2026.
- The mix effect from royalty-bearing products and its effect on gross margin.
Balance sheet and cash flow
- As of June 30, 2026, the Company had $360.2 million in unrestricted cash and cash equivalents.
- As of June 30, 2026, the Company had $274.5 million in net accounts receivable.
- As of June 30, 2026, the Company had $620.9 million in principal value of outstanding debt, inclusive of the Company’s senior convertible notes.
- The Company generated cash flow from operations of $115.0 million on a year to date basis.
Analysis
ANI reported record second-quarter total net revenues of $266.0 million, up 25.9% year-over-year. Rare Disease was the principal growth engine, with total net revenues increasing 30.7% to $135.8 million and Cortrophin Gel increasing 43.5% to $117.1 million. Generics also contributed, with generic pharmaceutical products increasing 9.7% to $99.1 million. Brand royalties and other revenues added $17.7 million, including development-milestone revenue and pitolisant-product royalties under the Harmony Agreement.
Cortrophin Gel demand remained broad across the existing specialties of Nephrology, Neurology, Ophthalmology, Pulmonology and Rheumatology. The company stated that its acute gouty arthritis expansion was fully operational by the end of June and reported favorable early demand indicators, including over 95% of reps generating multiple new patient cases and over a third of prescribers initiating two or more cases. Generics performance was supported by the partnered generic launch begun in the third quarter of 2025, additional product launches, and commercial and operational outperformance. Offsetting factors included a 16.1% decline in ILUVIEN and YUTIQ revenue due primarily to international shipment timing and a 10.5% decline in Brands revenue due to normalized demand for certain products.
Profitability improved in absolute terms despite lower gross margins. GAAP net income attributable to common shareholders was $24.7 million, compared with $8.1 million in the prior-year period, and GAAP diluted income per share was $1.05 versus $0.36. Adjusted non-GAAP EBITDA increased 32.4% to $71.6 million and adjusted non-GAAP diluted earnings per share rose to $2.21 from $1.80. However, GAAP gross margin declined from 64.7% to 62.4% and non-GAAP gross margin declined from 64.9% to 62.6%, primarily reflecting a greater mix of royalty-bearing products and the absence of prior-year Prucalopride revenue. Higher selling, general, and administrative expense included costs for the Rare Disease sales-force expansion.
ANI reaffirmed total company net revenue guidance of $1,080 million - $1,140 million, adjusted non-GAAP EBITDA guidance of $285 million - $300 million, and adjusted non-GAAP diluted EPS guidance of $9.19 - $9.69. It retained ILUVIEN guidance of $78 million - $83 million but revised Cortrophin Gel net revenue guidance to $520 million - $540 million from $540 million - $575 million. Liquidity included $360.2 million of unrestricted cash and cash equivalents, while principal debt outstanding was $620.9 million. The company generated $115.0 million of year-to-date operating cash flow and authorized a program to repurchase up to $100.0 million of common stock through May 2029.
Management, verbatim
In the second quarter, we delivered outstanding financial results, while we implemented the largest Rare Disease sales force expansion in our history.
Nikhil Lalwani, President and CEO of ANI
Leading indicators from our gout expansion for Cortrophin Gel are very positive, with the team rapidly delivering a large funnel of new patient cases, with significant breadth and depth of prescribing.
Nikhil Lalwani, President and CEO of ANI
We are reaffirming our full year 2026 total net revenue guidance of $1,080 - $1,140 million and adjusted non-GAAP EBITDA of $285 - $300 million.
Nikhil Lalwani, President and CEO of ANI
Not in the filing
stated, not guessed- GAAP operating income
- Non-GAAP operating income
- Quarterly operating cash flow
- Free cash flow
- Cash flow from operations prior-year comparison
- Free cash flow prior-year comparison
- Quarterly debt change
- Capital returned through share repurchases during the quarter
- Dividend amount or dividend policy
- Prior-quarter comparisons for revenue, segments, margins, expenses, net income, EPS, and adjusted EBITDA
- Prior-year dollar amount for adjusted non-GAAP EBITDA
- Prior-year dollar amounts for GAAP and non-GAAP research and development expenses
- Prior-year dollar amounts for GAAP and non-GAAP selling, general, and administrative expenses
- Full-year 2026 operating-expense guidance
- Actual full-year 2026 results for comparison with prior full-year guidance
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC Form 8-K (Item 2.02) with ANI’s Q2 2026 financial results and business highlights, including Rare Disease growth initiatives and updated segment guidance.
Ticker impact
ANI reported Q2 2026 results and reaffirmed 2026 guidance, including Cortrophin Gel net revenue guidance of $520-$540 million.
Bias toward upside as long as investors view the gout expansion demand metrics as durable and the updated Cortrophin Gel range as achievable.
The filing discloses multiple hard datapoints (Q2 revenue, GAAP and non-GAAP EPS, and full-year guidance ranges) and a specific Cortrophin Gel guidance update tied to gout expansion execution.
Market effects
Rare disease and specialty pharma investors may re-rate execution risk if Cortrophin Gel expansion indicators translate into sustained prescription growth.
Limited direct regional spillover; primarily affects US small/mid-cap biotech and specialty pharma sentiment.
Modest, since the disclosed guidance is company-specific; international shipment timing impacted ILUVIEN but is not presented as a global structural issue.
Counterpoint
Cortrophin Gel guidance is only modestly adjusted, so the market may still focus on gross margin pressure and the risk that expansion demand metrics do not convert into durable revenue.
Key entities
- issuerANI Pharmaceuticals, Inc.
Nasdaq-listed company reporting Q2 2026 results, reaffirming 2026 guidance, and updating Cortrophin Gel net revenue guidance.
- productCortrophin Gel
Rare disease product with Q2 net revenues of $117.1 million and updated 2026 net revenue guidance of $520-$540 million.
- productILUVIEN
Rare disease product with Q2 net revenues of $18.7 million, down 16.1% year over year due to shipment timing.
- revenue arrangementHarmony Agreement
ANI recognized $17.7 million in Q2 revenue under the Harmony Agreement, including royalties and development milestone work.
- corporate actionShare repurchase program
Board authorized repurchases up to $100.0 million through May 2029, effective May 8, 2026.
